Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Summary

This is a Phase 1, randomized, open-label, single center, three period crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 12 healthy female subjects will be enrolled in this study.

Timeline

Start

2009-10

Primary completion

2009-12

Completion

2010-01

Drugs

Indications

No indication recorded.